Metojectpen (Metoject) Stungulyf, lausn í áfylltum lyfjapenna 12,5 mg Исланд - Исландски - LYFJASTOFNUN (Icelandic Medicines Agency)

metojectpen (metoject) stungulyf, lausn í áfylltum lyfjapenna 12,5 mg

medac gesellschaft für klinische spezialpräparate gmbh - methotrexatum inn - stungulyf, lausn í áfylltum lyfjapenna - 12,5 mg

Metojectpen (Metoject) Stungulyf, lausn í áfylltum lyfjapenna 15 mg Исланд - Исландски - LYFJASTOFNUN (Icelandic Medicines Agency)

metojectpen (metoject) stungulyf, lausn í áfylltum lyfjapenna 15 mg

medac gesellschaft für klinische spezialpräparate gmbh - methotrexatum inn - stungulyf, lausn í áfylltum lyfjapenna - 15 mg

Metojectpen (Metoject) Stungulyf, lausn í áfylltum lyfjapenna 22,5 mg Исланд - Исландски - LYFJASTOFNUN (Icelandic Medicines Agency)

metojectpen (metoject) stungulyf, lausn í áfylltum lyfjapenna 22,5 mg

medac gesellschaft für klinische spezialpräparate gmbh - methotrexatum inn - stungulyf, lausn í áfylltum lyfjapenna - 22,5 mg

Duac Hlaup Исланд - Исландски - LYFJASTOFNUN (Icelandic Medicines Agency)

duac hlaup

stiefel laboratories legacy (ireland) ltd - benzoylis peroxidum; clindamycinum fosfat - hlaup

Sotyktu Европска Унија - Исландски - EMA (European Medicines Agency)

sotyktu

bristol-myers squibb pharma eeig - deucravacitinib - psoriasis - Ónæmisbælandi lyf - treatment of moderate-to-severe plaque psoriasis in adults.

Metoject Stungulyf, lausn í áfylltri sprautu 50 mg/ml Исланд - Исландски - LYFJASTOFNUN (Icelandic Medicines Agency)

metoject stungulyf, lausn í áfylltri sprautu 50 mg/ml

medac gesellschaft für klinische spezialpräparate gmbh - methotrexatum inn - stungulyf, lausn í áfylltri sprautu - 50 mg/ml

Adempas Европска Унија - Исландски - EMA (European Medicines Agency)

adempas

bayer ag - riociguat - háþrýstingur, lungnabólga - blóðþrýstingslækkandi lyf fyrir lungnaháþrýsting - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. verkun hefur verið sýnt fram í pah íbúa þar á meðal orsökum sjálfvakin eða arfgengum pah eða pah tengslum við tengdum vef sjúkdómur. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.